The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Young Disease: A Holistic Approach to the Treatment of Antiphospholipid Syndrome

A Young Disease: A Holistic Approach to the Treatment of Antiphospholipid Syndrome

September 8, 2022 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2022 (VIRTUAL)—Described only about 40 years ago, antiphospholipid syndrome (APS) is a relatively young disease. It wasn’t until 2019 that the European Alliance of Associations for Rheumatology (EULAR) published evidence-based recommendations for the management of APS in adults, and the ACR has not yet released clinical practice guidelines.1 Although progress is being made, we still have a lot of questions to answer regarding best management practices.

You Might Also Like
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • Antiphospholipid Syndrome
Explore This Issue
October 2022
Also By This Author
  • Remission Definitions in RA: Common Questions & Implications for Clinical Practice

At the EULAR 2022, Ricard Cervera, MD, PhD, senior consultant and head, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, Spain, described a holistic approach to the treatment of APS.

Dr. Cervera

Clot Risk

The incidence of first thrombosis depends on multiple factors, such as the antiphospholipid antibody (aPL) profile, which is defined by the aPL type, multiple vs. single aPL positivity, apL titers and the persistence of aPL positivity on repeated measurements.1 A high-risk aPL profile is defined as the presence—on two or more occasions at least 12 weeks apart—of a lupus anticoagulant, double or triple aPL positivity, or the presence of persistently high aPL titers.

The aPL profile helps determine the risk of thrombotic and obstetric events and informs the aggressiveness of treatment. Example: The incidence of events is less than one per 100 patient-years in aPL asymptomatic carriers, but rises to seven per 100 patient-years in patients with systemic lupus erythematosus (SLE) with obstetric APS.2 The EULAR recommendations for the management of APS in a patient vary based on aPL profile, history of thrombosis or obstetric complication, coexistence of other systemic autoimmune diseases and the presence of traditional cardiovascular risk factors.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Primary Thromboprophylaxis

Is there anything we can do to prevent clots from occurring in the first place? A 2007 randomized controlled trial—the APLASA study—showed no protective benefit of aspirin for primary thromboprophylaxis in asymptomatic aPL-positive individuals. However, a 2014 meta-analysis of 11 studies found asymptomatic aPL-positive patients treated with long-term, low-dose aspirin (75–100 mg daily) had a 50% risk reduction for occurrence of first clot.3 This finding held true for patients with SLE and obstetrical APS.

EULAR recommends low-dose aspirin for primary thromboprophylaxis in patients who have a high-risk aPL profile, SLE or obstetrical APS. Low-dose aspirin may also be considered for those with lower risk aPL profiles.1

Would anticoagulation added to aspirin also help prevent primary thrombosis? In 2014, the ALIWAPAS trial examined low-dose aspirin vs. low-dose aspirin plus low-intensity warfarin (i.e., international normalized ratio [INR] goal of 1.5) for primary thromboprophylaxis in aPL-positive individuals with SLE or obstetric morbidity (i.e., higher risk patients).4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: antiphospholipid syndrome, cardiovascular, catastrophic antiphospholipid syndrome, EULAR 2022, Glucocorticoids, patient careIssue: October 2022

You Might Also Like:
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • Antiphospholipid Syndrome
  • ACR/ARHP Annual Meeting 2012: Tips to Diagnose and Treat Catastrophic Antiphospholipid Syndrome (CAPS)

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)